Boston: A conference to discuss the future of anti-aging medicines is held at Harvard Medical School. The school’s dean opened the event and key speakers from industry and academia gave short talks. The event was covered by the New York Times in an article titled: Quest for a Long Life Gains Scientific Respect. The paper reported that SRT-501, GSK’s special formulation of resveratrol, is being tested against two cancers, multiple myeloma and colon cancer that has spread to the liver. A chemical mimic of resveratrol, known as SRT-2104, is in a Phase 2 trial for Type 2 diabetes, and in a Phase 1 trial in elderly patients. Rapamycin was also raised as a possible lifespan extending drug but with known side effects.
Comments are closed.